APOA1 and Alzheimer disease: Particularly, Slot et al. measured ApoA-1 levels in the CSF of elderly people with cognitive decline (SCD) and MCI, detecting increased levels of the protein in APOE ε4 carriers with cognitive decline and confirming its role as a biomarker in the early stages of AD [68].